Eli Lilly's obesity lead is only the starting point. See what its pipeline, manufacturing build-out, pricing pressure, and earnings trajectory could mean for the stock's next chapter.
Eli Lilly & Co. (LLY) News
Latest headlines that mention LLY, newest first · each headline opens the original publisher
- Last price
- $1,169.60
- Day change
- -1.61%
- Next earnings
- 2026-10-29 BMO
LLY headlines
last 30 daysThe company is far from a one-trick pony.
People have long been willing to pay for healthcare despite rising costs, with Medtronic and Eli Lilly offering two different angles on the space.
Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.
The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.
Eli Lilly is partnering with Ginkgo Bioworks on drug discovery.
Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.
Can anyone stop Eli Lilly’s progress in the weight loss market?
The company is the leader in a key growth market.
One-third of all new patients starting an oral GLP-1 medication are now choosing Foundayo.
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
The company is constantly thinking big.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Also mentioned with LLY
30dHeadlines that tag both tickers
LLY news alerts
Get an alert by email or push when a new headline mentions LLY.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.